RAFAEL HOLDINGS INC. CLASS B COMMON STOCK

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

11 12 2024 07:00:00 提供 Nasdaq GlobeNewswire

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

06 11 2024 19:14:00 提供 Nasdaq GlobeNewswire

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

22 8 2024 06:50:00 提供 Nasdaq GlobeNewswire

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

14 6 2024 16:01:00 提供 Nasdaq GlobeNewswire

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

13 3 2024 17:04:24 提供 Nasdaq GlobeNewswire

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

14 12 2023 16:01:00 提供 Nasdaq GlobeNewswire

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

30 10 2023 16:01:00 提供 Nasdaq GlobeNewswire

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

13 6 2023 16:01:00 提供 Nasdaq GlobeNewswire

Rafael Holdings Announces up to $5 Million Share Repurchase Program

04 4 2023 08:00:01 提供 Nasdaq GlobeNewswire

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

14 3 2023 16:01:00 提供 Nasdaq GlobeNewswire

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

13 12 2022 07:00:00 提供 Nasdaq GlobeNewswire

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

15 11 2022 16:01:00 提供 Nasdaq GlobeNewswire

Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results

31 10 2022 16:01:00 提供 Nasdaq GlobeNewswire

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

28 9 2022 07:00:00 提供 Nasdaq GlobeNewswire

Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage

23 8 2022 07:43:22 提供 Nasdaq GlobeNewswire

Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

03 8 2022 08:00:01 提供 Nasdaq GlobeNewswire

Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

06 7 2022 08:00:04 提供 Nasdaq GlobeNewswire

Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022

27 6 2022 08:00:01 提供 Nasdaq GlobeNewswire

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

16 6 2022 14:14:18 提供 Nasdaq GlobeNewswire

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

16 6 2022 08:00:01 提供 Nasdaq GlobeNewswire